American Association for Cancer Research
Browse
- No file added yet -

Supplementary Figures 1-4 from PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients

Download (6.78 MB)
journal contribution
posted on 2023-03-31, 20:12 authored by Nicholas P. Tobin, Arian Lundberg, Linda S. Lindström, J. Chuck Harrell, Theodoros Foukakis, Lena Carlsson, Zakaria Einbeigi, Barbro K. Linderholm, Niklas Loman, Martin Malmberg, Mårten Fernö, Kamila Czene, Charles M. Perou, Jonas Bergh, Thomas Hatschek

Supplementary Figure 1 CONSORT diagram, TEX cohort Supplementary Figure 2 Long term post-relapse BCSS for gene expression signatures Supplementary Figure 3 Short term post-relapse BCSS for gene expression signatures Supplementary Figure 4 Long and short term post-relapse BCSS Kaplan-Meier curves for PAM50 at specific metastatic sites

Funding

BRECT

Swedish Cancer Society

Cancer Society in Stockholm

King Gustaf V Jubilee Foundation

Swedish Breast Cancer Association

Swedish Research Council

Bristol-Myers Squibb Sweden AB

Pfizer Sweden AB

Roche Sweden AB

NCI Breast SPORE

Breast Cancer Research Foundation

History

ARTICLE ABSTRACT

Purpose: Transcriptional pathway activity and the molecular subtypes of breast cancer metastases have been shown to significantly influence patient postrelapse survival. Here, we further determine the relevance of clinically employed gene signatures in the advanced breast cancer (ABC) setting.Experimental Design: Sufficient RNA for expression profiling was obtained from distant metastatic or inoperable loco-regional relapse tissue by fine-needle aspiration from 109 patients of the Swedish TEX clinical trial. Gene signatures (GGI, 70 gene, recurrence score, cell-cycle score, risk of recurrence score, and PAM50) were applied to all metastases, and their relationship to long- (5-year) and short-term (1.5-year) postrelapse survival at all and locoregional lymph nodes (n = 40) versus other metastatic sites (n = 69) combined was assessed using Kaplan–Meier and/or multivariate Cox regression analyses.Results: The majority of metastases were classified into intermediate or high-risk groups by all signatures, and a significant association was found between metastatic signature subgroups and primary tumor estrogen receptor status and histologic grade (P < 0.05). When considering all sites of metastasis, only PAM50 was statistically significant in Kaplan–Meier analysis (Log-rank P = 0.008 and 0.008 for long- and short-term postrelapse breast cancer–specific survival, respectively). This significance remained in both uni- and multivariate models when restricting analyses to lymph node metastases only, and a similar trend was observed in other metastatic sites combined, but did not reach formal significance.Conclusions: Our findings are the first to demonstrate that the PAM50 signature can provide prognostic information from the lymph node metastases of ABC patients. Clin Cancer Res; 23(23); 7225–31. ©2017 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC